THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL). The investigational study showed blinatumomab monotherapy induced a complete remission […]

July 14, 2015By Alex Keown, Breaking News Staff SUMMIT, N.J. – Celgene Corporation (CELG) has struck again, acquiring Receptos, Inc. (RCPT) for $7.2 billion to enhance the company’s inflammation and immunology portfolio. The acquisition was announced Tuesday afternoon. The acquisition brings some key drugs into Celgene’s pipeline, including Ozanimod, an oral once-daily, selective sphingosine […]

July 15, 2015By Alex Keown, Breaking News Staff CAMBRIDGE, Mass. –All eyes will be focused on Biogen, Inc. next week as the pharmaceutical company is expected to reveal the latest data in its Alzheimer’s trial – data that could lead to either a breakthrough or another roadblock for Alzheimer’s care. There is currently no […]

Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. Celgene, whose shares rose nearly 6 percent in extended trading to $130.15, said it would pay $232 […]